![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FCRL5 |
Gene summary for FCRL5 |
![]() |
Gene information | Species | Human | Gene symbol | FCRL5 | Gene ID | 83416 |
Gene name | Fc receptor like 5 | |
Gene Alias | BXMAS1 | |
Cytomap | 1q23.1 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q96RD9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
83416 | FCRL5 | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 2.52e-09 | 8.28e-01 | 0.1479 |
83416 | FCRL5 | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 2.22e-03 | 5.26e-01 | 0.1531 |
83416 | FCRL5 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 3.50e-02 | 4.14e-01 | 0.1619 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Prostate | ![]() | BPH: Benign Prostatic Hyperplasia |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FCRL5 | SNV | Missense_Mutation | c.854C>A | p.Ser285Tyr | p.S285Y | Q96RD9 | protein_coding | deleterious(0.02) | probably_damaging(0.986) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
FCRL5 | SNV | Missense_Mutation | novel | c.400A>G | p.Thr134Ala | p.T134A | Q96RD9 | protein_coding | tolerated(0.24) | benign(0.304) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
FCRL5 | SNV | Missense_Mutation | novel | c.122N>T | p.Thr41Ile | p.T41I | Q96RD9 | protein_coding | deleterious(0.03) | benign(0.158) | TCGA-BG-A221-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FCRL5 | SNV | Missense_Mutation | c.1025N>T | p.Ser342Ile | p.S342I | Q96RD9 | protein_coding | tolerated(0.21) | possibly_damaging(0.883) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FCRL5 | SNV | Missense_Mutation | novel | c.95N>T | p.Thr32Ile | p.T32I | Q96RD9 | protein_coding | deleterious(0.01) | probably_damaging(0.936) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
FCRL5 | SNV | Missense_Mutation | c.2840A>G | p.Asn947Ser | p.N947S | Q96RD9 | protein_coding | tolerated(0.07) | benign(0.145) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FCRL5 | SNV | Missense_Mutation | rs753510908 | c.1235N>G | p.Tyr412Cys | p.Y412C | Q96RD9 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
FCRL5 | SNV | Missense_Mutation | novel | c.2068N>A | p.Leu690Met | p.L690M | Q96RD9 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FCRL5 | SNV | Missense_Mutation | c.2347N>A | p.Leu783Met | p.L783M | Q96RD9 | protein_coding | deleterious(0.05) | probably_damaging(0.958) | TCGA-EC-A1QX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | PD | |
FCRL5 | SNV | Missense_Mutation | novel | c.2461N>A | p.Ala821Thr | p.A821T | Q96RD9 | protein_coding | deleterious(0.01) | benign(0.065) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |